Vilazodon

Vilazodone is FDA-approved for major depressive disorder in adults. It combines SSRI activity with partial 5-HT1A receptor agonism, potentially offering advantages in side effect profile. Must be taken with food for adequate bioavailability (72% with food vs 50% reduction when fasting). Not approved for use in individuals under 18. Gradual titration recommended (10 mg for 7 days, then 20 mg for 7 days, then 40 mg maintenance).

Also known as: Viibryd, Emd 515259, Sb 659746a, Vilazodone hcl, EMD-68843

Classification

Chemical: Benzofuran
Chemical: Medicine
Chemical: Piperazine
Tag: Antidepressant
Tag: Indole derivative
Tag: Pharmaceutical
Tag: Ssri

Effects

Nausea
Diarrhea
Headache
Insomnia
Sedation
Sleep Fragmentation
Mood Lift
Anxiety Suppression
Dizziness
Mood Improvement In Depressed Individuals
Vivid Dreams
Anxiety
Sexual Dysfunction
Dehydration
Auditory Hallucination
Visual Acuity Suppression
External Hallucination
Light Sensitivity

Routes of Administration

Oral

Dosage

Threshold: 5 mg
Light: 10-20 mg
Common: 20-40 mg
Strong: 40 mg
Heavy: >40 mg (not recommended)

Duration

Onset: 1-2 h
Peak: 4-8 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu